SEC 13F Intelligence

Skandinaviska Enskilda Banken AB (Publ) / VRTX

Skandinaviska Enskilda Banken AB (Publ)’s Vertex Pharmaceuticals Inc Position

Does Skandinaviska Enskilda Banken AB (Publ) own Vertex Pharmaceuticals Inc (VRTX)? Yes — 46.0K shares worth $21M (+0.47% of its 13F portfolio) as of Q1 2026, down from 174.5K shares the prior filed quarter.

Position Value
$21M
Q1 2026
Shares
46.0K
% of Portfolio
+0.47%
Quarters Held
30
currently held

Position History VRTX

Reported value by quarter
Q4 ’18: $14MQ4 ’18Q1 ’19: $20MQ2 ’19: $18MQ3 ’19: $19MQ4 ’19: $25MQ4 ’19Q1 ’20: $41MQ2 ’20: $81MQ3 ’20: $73MQ4 ’20: $63MQ4 ’20Q1 ’21: $74MQ2 ’21: $62MQ3 ’21: $54MQ4 ’21: $64MQ4 ’21Q1 ’22: $61MQ2 ’22: $71MQ3 ’22: $102MQ4 ’22: $117,399Q4 ’22Q1 ’23: $139,892Q2 ’23: $132,651Q3 ’23: $113,628Q4 ’23: $99MQ4 ’23Q1 ’24: $111MQ2 ’24: $103MQ3 ’24: $86MQ4 ’24: $68MQ4 ’24Q1 ’25: $90MQ2 ’25: $79MQ3 ’25: $60MQ4 ’25: $79MQ4 ’25Q1 ’26: $21Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202646.0K$21M+0.47%
Q4 2025174.5K$79M+0.32%
Q3 2025154.2K$60M+0.24%
Q2 2025176.6K$79M+0.34%
Q1 2025186.5K$90M+0.45%
Q4 2024171.0K$68M+0.31%
Q3 2024185.3K$86M+0.40%
Q2 2024218.8K$103M+0.49%
Q1 2024264.9K$111M+0.54%
Q4 2023243.7K$99M+0.57%
Q3 2023326.6K$113,628+0.75%
Q2 2023376.9K$132,651+0.87%
Q1 2023444.0K$139,892+0.98%
Q4 2022406.5K$117,399+0.88%
Q3 2022351.7K$102M+0.79%
Q2 2022253.3K$71M+0.52%
Q1 2022232.0K$61M+0.36%
Q4 2021287.9K$64M+0.33%
Q3 2021298.1K$54M+0.30%
Q2 2021306.6K$62M+0.38%
Q1 2021345.2K$74M+0.49%
Q4 2020266.4K$63M+0.43%
Q3 2020268.7K$73M+0.53%
Q2 2020278.5K$81M+0.65%
Q1 2020173.1K$41M+0.44%
Q4 2019115.3K$25M+0.20%
Q3 2019111.7K$19M+0.16%
Q2 201998.2K$18M+0.16%
Q1 2019106.4K$20M+0.18%
Q4 201882.6K$14M+0.12%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Skandinaviska Enskilda Banken AB (Publ)’s full portfolio or all institutional holders of VRTX.